BEAM vs KRRO
BEAM: Beam Therapeutics is a biotechnology firm pioneering base editing technology to create next-generation precision genetic medicines. KRRO: Korro Bio is a clinical-stage genetic medicine company using its proprietary OPERA platform to develop precise, transient RNA-editing therapies for rare and complex diseases.
Side-by-side fundamentals
| Metric | BEAM | KRRO | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $24.93 | $9.44 | |
| Market cap | $2.6B | $139M | |
| Net margin FY2025, SEC XBRL | -57.2% | -1834.5% | BEAM higher |
| Operating margin FY2025, SEC XBRL | -274.6% | -1906.4% | BEAM higher |
| ROE FY2025, SEC XBRL | -6.5% | -228.0% | BEAM higher |
| ROA FY2025, SEC XBRL | -5.4% | -103.3% | BEAM higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.09 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +120.0% | +181.5% | KRRO higher |
| Revenue CAGR (3y) SEC XBRL | +31.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.82 | 1.79 | |
| 1-year return as of 2026-10-20 close | -18.6% | -79.6% | BEAM higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.